Recent progress in elucidating the mechanisms underlying human disease has dramatically increased the number of protein targets available for potential drug treatment. Concurrently, new approaches have increased the number of compounds that can be tested for activity against these targets. Together, these trends have stimulated the adoption of high-throughput screening as a primary tool for early-stage drug discovery.